TsewangTashiMD
Hematology • Salt Lake City, UTHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah
Dr. Tashi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Circle of Hope Dr
Ste 2100
Salt Lake City, UT 84112Phone+1 801-585-0120Fax+1 801-585-0124
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2012 - 2015
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2008 - 2011
Chang Gung University College of MedicineClass of 2003, MD
Certifications & Licensure
UT State Medical License 2012 - 2026
VA State Medical License 2011 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Start of enrollment: 2018 Nov 21
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Start of enrollment: 2016 Mar 10
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis Start of enrollment: 2019 Apr 16
- Join now to see all
Publications & Presentations
PubMed
- Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS.Peng Li, F N U Alnoor, Wei Xie, Margaret Williams, Julie Feusier
Leukemia. 2024-11-08 - Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.Tsewang Tashi, Michael W Deininger
Immunology and Allergy Clinics of North America. 2023-11-01 - 12 citationsAvapritinib versus Placebo in Indolent Systemic Mastocytosis.Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, Frank Siebenhaar, Karin Hartmann
NEJM Evidence. 2023-06-01
Professional Memberships
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin), Hindi, Urdu, French, Taiwanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
